Skip to main
PRQR

ProQR Therapeutics (PRQR) Stock Forecast & Price Target

ProQR Therapeutics (PRQR) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProQR Therapeutics is a promising biopharmaceutical company with a strong focus on developing RNA therapeutics for rare genetic diseases. Their recent target engagement data and successful fundraising efforts indicate a positive direction for the company's operational and financial outlook. However, investors should be aware of risks such as potential safety concerns and competition, as well as the potential need for additional funding in the future. Nevertheless, ProQR's innovative approach to RNA editing and its promising pipeline make it a company to watch for potential growth and success in the future.

Bears say

ProQR Therapeutics is a biopharmaceutical company that discovers and develops RNA therapeutics for rare genetic diseases. The company operates in the United States and focuses on the development of RNA-based therapeutics. However, with a continuing cash burn and potential future need to raise capital, there is uncertainty around the company's financial stability and ability to fully develop and commercialize its products. Additionally, the intensely competitive nature of the biotechnology and pharmaceutical industries, coupled with regulatory risks and potential safety concerns, could hinder the company's success. It may be difficult for the company to secure funding in the future, which could impact the progress of its research and development programs. Ultimately, these risks could lead to ProQR Therapeutics' therapies becoming non-competitive or obsolete, resulting in a negative outlook for the company's stock.

ProQR Therapeutics (PRQR) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProQR Therapeutics (PRQR) Forecast

Analysts have given ProQR Therapeutics (PRQR) a Strong Buy based on their latest research and market trends.

According to 4 analysts, ProQR Therapeutics (PRQR) has a Strong Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProQR Therapeutics (PRQR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.